{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T15:40:33Z","timestamp":1659886833747},"reference-count":46,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2017.5526","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T10:05:15Z","timestamp":1510913115000},"source":"Crossref","is-referenced-by-count":0,"title":["Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir\/ritonavir)-induced lipodystrophy and metabolic syndrome in mice"],"prefix":"10.3892","author":[{"given":"Tomokazu","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumasa","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohide","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Kaneki","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"key20200713143454_b1-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","article-title":"HIV epidemiology and the effects of antiviral therapy on long-term consequences","volume":"22","author":"Quinn","year":"2008","journal-title":"AIDS"},{"key":"key20200713143454_b2-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1210\/jcem.84.6.5740","article-title":"Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy","volume":"84","author":"Yanovski","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200713143454_b3-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"e63623","DOI":"10.1371\/journal.pone.0063623","article-title":"Systematic review of antiretroviral-associated lipodystrophy: Lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction","volume":"8","author":"de Waal","year":"2013","journal-title":"PLoS One"},{"key":"key20200713143454_b4-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.med.58.072905.180040","article-title":"Cardiovascular risks of antiretroviral therapies","volume":"58","author":"Mondy","year":"2007","journal-title":"Annu Rev Med"},{"key":"key20200713143454_b5-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/01.aids.0000327512.76126.6e","article-title":"Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors","volume":"22","author":"Boccara","year":"2008","journal-title":"AIDS"},{"key":"key20200713143454_b6-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"e0117125","DOI":"10.1371\/journal.pone.0117125","article-title":"Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV\/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia","volume":"10","author":"Gleason","year":"2015","journal-title":"PLoS One"},{"key":"key20200713143454_b7-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"key20200713143454_b8-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jinf.2008.02.006","article-title":"Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy","volume":"57","author":"Calza","year":"2008","journal-title":"J Infect"},{"key":"key20200713143454_b9-etm-0-0-5526","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","author":"WHO Guidelines Approved by the Guidelines Review Committee","year":"2015"},{"key":"key20200713143454_b10-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV medical association of the infectious disease society of America and the adult AIDS clinical trials group","volume":"37","author":"Dub\u00e9","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key20200713143454_b11-etm-0-0-5526","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"key20200713143454_b12-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/QAI.0000000000000581","article-title":"Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study","volume":"69","author":"Lichtenstein","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key20200713143454_b13-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","article-title":"Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors","volume":"52","author":"Chauvin","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"key20200713143454_b14-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature01629","article-title":"Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome","volume":"423","author":"Eriksson","year":"2003","journal-title":"Nature"},{"key":"key20200713143454_b15-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/sj.cdd.4402197","article-title":"Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence","volume":"14","author":"Caron","year":"2007","journal-title":"Cell Death Differ"},{"key":"key20200713143454_b16-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/ajmg.a.31346","article-title":"Hutchinson-Gilford progeria syndrome: Review of the phenotype","volume":"140","author":"Hennekam","year":"2006","journal-title":"Am J Med Genet A"},{"key":"key20200713143454_b17-etm-0-0-5526","doi-asserted-by":"crossref","first-page":"16321","DOI":"10.1016\/S0021-9258(19)85424-8","article-title":"Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C","volume":"268","author":"Lin","year":"1993","journal-title":"J Biol Chem"},{"key":"key20200713143454_b18-etm-0-0-5526","unstructured":"BergoMOGavinoBRossJSchmidtWKHongCKendallLVMohrAMetaMGenantHJiangYZmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defectProc Natl Acad Sci USA991304913054200210.1073\/pnas.19246079912235369"},{"key":"key20200713143454_b19-etm-0-0-5526","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/ng871","article-title":"Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice","volume":"31","author":"Pend\u00e1s","year":"2002","journal-title":"Nat Genet"},{"key":"key20200713143454_b20-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1074\/jbc.271.10.5289","article-title":"Protein prenyltransferases","volume":"271","author":"Casey","year":"1996","journal-title":"J Biol Chem"},{"key":"key20200713143454_b21-etm-0-0-5526","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1096\/fasebj.4.15.2123808","article-title":"Posttranslational modification of proteins by isoprenoids in mammalian cells","volume":"4","author":"Maltese","year":"1990","journal-title":"FASEB J"},{"key":"key20200713143454_b22-etm-0-0-5526","unstructured":"CoffinierCHudonSEFarberEAChangSYHrycynaCAYoungSGFongLGHIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cellsProc Natl Acad Sci USA1041343213437200710.1073\/pnas.070421210417652517"},{"key":"key20200713143454_b23-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"171ps3","DOI":"10.1126\/scitranslmed.3005229","article-title":"Targeting protein prenylation in progeria","volume":"5","author":"Young","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20200713143454_b24-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.113.008285","article-title":"Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome","volume":"130","author":"Gordon","year":"2014","journal-title":"Circulation"},{"key":"key20200713143454_b25-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1161\/ATVBAHA.110.213603","article-title":"Premature senescence of vascular cells is induced by HIV protease inhibitors: Implication of prelamin A and reversion by statin","volume":"30","author":"Lef\u00e8vre","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20200713143454_b26-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.antiviral.2010.10.006","article-title":"Metabolic and neurologic consequences of chronic lopinavir\/ritonavir administration to C57BL\/6 mice","volume":"88","author":"Pistell","year":"2010","journal-title":"Antiviral Res"},{"key":"key20200713143454_b27-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1128\/AAC.00625-06","article-title":"Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice","volume":"50","author":"Prot","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200713143454_b28-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1086\/382531","article-title":"Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir","volume":"38","author":"Mart\u00ednez","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key20200713143454_b29-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/jac\/dki063","article-title":"Lipid disorders in antiretroviral-naive patients treated with lopinavir\/ritonavir-based HAART: Frequency, characterization and risk factors","volume":"55","author":"Montes","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key20200713143454_b30-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/377527a0","article-title":"Transient increase in obese gene expression after food intake or insulin administration","volume":"377","author":"Saladin","year":"1995","journal-title":"Nature"},{"key":"key20200713143454_b31-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nm1195-1155","article-title":"Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects","volume":"1","author":"Maffei","year":"1995","journal-title":"Nat Med"},{"key":"key20200713143454_b32-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"key20200713143454_b33-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1210\/jc.2002-021600","article-title":"Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices","volume":"88","author":"Tong","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200713143454_b34-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/QAD.0000000000000186","article-title":"Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men","volume":"28","author":"Ketlogetswe","year":"2014","journal-title":"AIDS"},{"key":"key20200713143454_b35-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00125-005-0085-3","article-title":"In treatment-na\u00efve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL IDL and LDL apolipoprotein B-100","volume":"49","author":"Das","year":"2006","journal-title":"Diabetologia"},{"key":"key20200713143454_b36-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2165\/11204950-000000000-00000","article-title":"Lopinavir\/Ritonavir: A review of its use in the management of HIV-1 infection","volume":"70","author":"Croxtall","year":"2010","journal-title":"Drugs"},{"key":"key20200713143454_b37-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1097\/01.aids.0000237365.18747.13","article-title":"National adult antiretroviral therapy guidelines in resource-limited countries: Concordance with 2003 WHO guidelines?","volume":"20","author":"Beck","year":"2006","journal-title":"AIDS"},{"key":"key20200713143454_b38-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"key20200713143454_b39-etm-0-0-5526","first-page":"201027","article-title":"Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: Effects of antiretroviral therapy and adipose tissue distribution","volume":"2012","author":"van Wijk","year":"2012","journal-title":"Int J Vasc Med"},{"key":"key20200713143454_b40-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/apc.2013.0159","article-title":"A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir\/ritonavir dosage in pregnancy","volume":"27","author":"Bonafe","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"key20200713143454_b41-etm-0-0-5526","unstructured":"CapellBCOliveMErdosMRCaoKFaddahDATavarezULConneelyKNQuXSanHGaneshSKA farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse modelProc Natl Acad Sci USA1051590215907200810.1073\/pnas.080784010518838683"},{"key":"key20200713143454_b42-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/13543781003801076","article-title":"Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: Current understanding and recommended use of tipifarnib","volume":"19","author":"Epling-Burnette","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"key20200713143454_b43-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00280-012-1972-1","article-title":"Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2\/neu overexpressing breast cancer: EORTC study 16023","volume":"71","author":"Milojkovic Kerklaan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20200713143454_b44-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00280-006-0215-8","article-title":"Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib","volume":"58","author":"Perez-Ruixo","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20200713143454_b45-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF03190407","article-title":"Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors","volume":"27","author":"Crul","year":"2002","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"key20200713143454_b46-etm-0-0-5526","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2125.2006.02615.x","article-title":"Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients","volume":"62","author":"Perez-Ruixo","year":"2006","journal-title":"Br J Clin Pharmacol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T15:17:52Z","timestamp":1659885472000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.5526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3892\/etm.2017.5526","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]}}}